Potassium channel subfamily K member 2 and 10 (TREK-1/2)

TREK-1 (KCNK2) and TREK-2 (KCNK10) are members of the two-pore domain potassium (K2P) channel family, functioning as background or "leak" channels that are fundamental in setting the resting membrane potential and controlling cellular excitability [1, 4]. These channels are uniquely polymodal, responding to a wide range of physiological stimuli including mechanical stretch, temperature changes, intracellular pH, and bioactive lipids such as arachidonic acid [6, 8]. They are predominantly expressed in the central nervous system, heart, and various smooth muscle tissues, where they contribute to processes like neuroprotection, pain perception, and mood regulation [3, 6]. In pathological states, TREK-1 and TREK-2 are implicated in depression, chronic pain, and ischemic injury; for instance, TREK-1 deficiency or inhibition is associated with antidepressant-like behavior in animal models [3, 15]. Pharmacologically, these channels are sensitive to diverse agents, including volatile anesthetics, which activate them to induce hyperpolarization, and certain antidepressants like fluoxetine, which act as inhibitors [4, 12]. Recent evidence also demonstrates that TREK-1 and TREK-2 can form functional heterodimers, further diversifying the regulatory landscape of background potassium currents [13]. Targeting these channels offers therapeutic potential for treating neurological disorders, managing pain, and protecting against cardiovascular or respiratory inflammation [14, 16].

Other names

KCNK2KCNK10K2P2.1K2P10.1TPKC1TWIK-related potassium channel 1TWIK-related potassium channel 2TREK-1TREK-2

Modulation of background potassium conductance to regulate membrane potential; activation leads to hyperpolarization and reduced excitability (analgesia, neuroprotection), while inhibition leads to depolarization and increased excitability (antidepressant effect) [3, 4, 14].